UBS Group
CTXRW

UBS Group’s Citius Pharmaceuticals, Inc. Warrant CTXRW Stock Holding History

UBS Group’s Portfolio CTXRW Stock Details CTXRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-117
Closed – – 11765
2022
Q2 		$0 Sell
117
-86
-42% -$20 ﹤0.01% 11607
2022
Q1 		$0 Buy
203
+107
+111% +$49 ﹤0.01% 11457
2021
Q4 		$0 Buy
+96
New +$59 ﹤0.01% 11193
2021
Q2 		– Sell
-30
Closed – – 10172
2021
Q1 		$0 Buy
+30
New +$23 ﹤0.01% 9753
2020
Q2 		– Sell
-3,826
Closed -$1K – 8544
2020
Q1 		$1K Sell
3,826
-2,375
-38% -$929 ﹤0.01% 7859
2019
Q4 		$1K Buy
6,201
+26
+0.4% +$4 ﹤0.01% 8022
2019
Q3 		$1K Hold
6,175
– – ﹤0.01% 7885
2019
Q2 		$1K Buy
6,175
+5,400
+697% +$1.52K ﹤0.01% 7764
2019
Q1 		$0 Sell
775
-325
-30% -$90 ﹤0.01% 8360
2018
Q4 		$0 Buy
1,100
+100
+10% +$14 ﹤0.01% 8436
2018
Q3 		$0 Buy
+1,000
New +$333 ﹤0.01% 8392
2018
Q1 		– Sell
-4,265
Closed -$2K – 8305
2017
Q4 		$2K Buy
4,265
+1,100
+35% +$760 ﹤0.01% 7651
2017
Q3 		$2K Buy
+3,165
New +$2.05K ﹤0.01% 7507

UBS Group's CTXRW Position: Q3 2022 in Review

UBS Group sold out of Citius Pharmaceuticals, Inc. Warrant (CTXRW) in Q3 2022, closing a stake of 117 shares.

UBS Group first reported a position in CTXRW in Q3 2017 and held it in 13 quarters. The position peaked at $2K in Q4 2017. 0 funds tracked by Wall St. Rank hold CTXRW as of Q3 2022.

  • UBS Group reported no remaining Citius Pharmaceuticals, Inc. Warrant position as of Q3 2022 after selling out during the quarter.
  • UBS Group sold 117 Citius Pharmaceuticals, Inc. Warrant shares in Q3 2022.
  • UBS Group first reported a position in Citius Pharmaceuticals, Inc. Warrant in Q3 2017 and held it in 13 quarters.
  • UBS Group's Citius Pharmaceuticals, Inc. Warrant position peaked at $2K in Q4 2017.
  • 0 funds tracked by Wall St. Rank held Citius Pharmaceuticals, Inc. Warrant as of Q3 2022.

Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.